PTGS1 and neoplasm: Theoretically, COX inhibition is an attractive option in patients receiving angiogenesis inhibitor therapy as other benefits including a reduction in thrombotic tendency which is COX-1/TP receptor mediated [21,48] and the inhibition of tumour growth and prevention of resistance to angiogenesis-inhibitor therapy, which are both linked to COX-2 [49–53], are likely to be present as well.